Registration Open Programme Exhibition & Sponsorship Satellite Symposia
Please note that all times are in Central European Summer Time (CEST)
Programme Filter10.15
S. Rizzo ITALY
The restless fight against inherited blindness
10.45
B. Chanana INDIA
Management of dropped IOL and nucleus
10.51
S.J. Chen TAIWAN
Inadvertent globe perforation during local anaesthesia for cataract surgery and its Management
10.57
H. Heimann UK
Retinal detachment in mismanaged cataract surgery: Prevention, etiology, and management
11.03
K. Fong MALAYSIA
Cystoid macular edema: When and how to treat?
11.09
M. Zinckernagel SWITZERLAND
Endophthalmitis: early detection, differentiation from sterile reaction, and management
11.15
Discussion
11.30
End of session
11.00
U. Schmidt-Erfurth AUSTRIA
Neovascular AMD: AI evidence on novel grounds
11.06
S. Sivaprasad UK
Diabetic retinopathy severity: Diagnostic and therapeutic guidance
11.12
R. Tadayoni FRANCE
Surgery of (pseudo) holes: Standards in macular surgery
11.18
A. Loewenstein ISRAEL
Heads-up surgery: More options than ever
11.24
C.C.W. Klaver THE NETHERLANDS
The myopia pandemic: The European response
11.30
Discussion
11.45
End of session
11.45
G. Pertile ITALY
Introduction
11.47
G. Prigione ITALY
Strategies to deal with an intraocular foreign body
11.54
G. Caputo FRANCE
Foreign bodies and perforating traumas in children
12.01
H. Mortada
Management of late complications correlated with foreign body injuries
12.08
G. Pertile ITALY
Pitfalls in removing intraocular foreign bodies
12.15
Discussion
12.30
End of session
11.45
S. Vujosevic ITALY
Nomenclature of qualitative and quantitative OCTA parameters
11.53
M. Munk SWITZERLAND
Consensus on OCTA metrics in retinal vascular diseases and standardization of OCTA parameters in clinical trials
12.01
F. Pichi UAE
Consensus on OCTA metrics in inflammatory diseases
12.09
U. Chakravarthy UK
The Unicorn: Expert consensus on OCT A nomenclature in exudative AMD
12.17
Discussion
12.30
End of session
12.00
A. Laidlaw UK
Realistic expectations in complex retinal detachment surgery
12.05
B. Corcóstegui SPAIN
Encirclement: what does it do? when to use it?
12.10
J. Garcia-Arumi SPAIN
PVR, when how and what to peel
12.15
T. Williamson UK
Retinectomy in PVR: early vs late
12.20
J.C. Pastor SPAIN
Risks with Tamponade agents
12.25
Discussion
12.45
End of session
13.45
M. Batataglia Parodi ITALY
Multimodal diagnostic tools in DME
13.50
R. Cano Hidalgo MEXICO
Angio SS OCT in DME
13.55
V. Chong UK
The role of laser in DME
14.00
D. E. Pelayes argentina
New trends of pharmacotherapy in DME
14.05
F. Fayyad JORDAN
Mastering surgical management
14.10
F. March de Ribot SPAIN
Combining lines in DME and proliferative retinopathy
14.15
Discussion
14.30
End of session
13.45
B. Bodaghi FRANCE
Overall role of local therapy and indications in NIU-PS
13.50
C. Pavesio UK
Local and/or systemic strategies: what is the best option for each patient?
13.55
Z. Habot-Wilner ISRAEL
Local therapeutic armamentarium: from A to Z
14.00
U. Pleyer GERMANY
Common complications of local therapies and their management
14.05
Q.D. Nguyen USA
Local Treatment in Development for Uveitis
14.10
M. de Smet SWITZERLAND
Best examples of therapeutic management in current practice
14.15
Discussion
14.30
End of session
14.00
E. Pilotto ITALY
Retinopathy in Type 1 diabetic children
14.06
A. Fawzi USA
Retinal blood flow in diabetic retinopathy
14.12
M. Paques FRANCE
Deferred laser in DME: follow ETDRS or aim for TelCaps?
14.18
N. Bressler USA
Current and future DRCRnet protocols in diabetic retinopathy
14.24
A. Laidlaw UK
Surgical solutions for DR, when to go in
14.30
Discussion
14.45
End of session
14.45
J. Monés SPAIN
Introduction
14.50
G. Staurenghi ITALY
The new nomenclature for AMD
14.58
K. Csaky USA
The role of functional testing in AMD
15.06
J. Monés SPAIN
New and future treatments for AMD
15.14
Discussion
15.30
End of session
14.45
T. Rossi ITALY
Welcome and Introduction
14.48
T. Hassan USA
More options for wide-field viewing — back to the future
14.51
P. Stalmans BELGIUM
First reported clinical results from end-stage RP patients implanted with an innovative 3D- neural interface retinal prosthesis
14.54
S. Charles USA
Medium term PFO for inferior RDs, giant breaks (except superior) and macular patch grafts.
14.57
T. Rossi ITALY
Novel instrument for ILM, amniotic and retinal flap manipulation
14.59
D. Steel UK
Sphere of influence and fluctuations in flow during vitrectomy – effect of cutter design
15.02
M. De Smet SWITZERLAND
Optimizing subretinal delivery via robotics
15.05
S. Rizzo ITALY
A novel multi-function instrument
15.08
Discussion
15.30
End of session
15.00
P. Keane UK
Artificial Intelligence in OCT and fundus images: Overview
15.07
T. Peto UK
Artificial Intelligence for DR screening
15.11
R. Tadayoni FRANCE
From DRSS to new imaging and AI
15.15
R. Sznitman SWITZERLAND
Biomarker detection in OCT scans
15.19
S. Sadda USA
Deep learning for assessment of AMD biomarkers
15.23
R. Schwartz UK
Using deep learning to detect reticular pseudodrusen on the UK Biobank – results and implications
15.27
Discussion
15.45
End of session
15.45
T. Jackson UK
Designing, executing and interpreting randomized clinical trials
15.53
L. Kodjikian FRANCE
From randomized clinical trial to real-world: efficacy of VEGF inhibitors
16.01
O. Zeitz GERMANY
Understanding safety data: From adverse events to undesirable effects
16.08
A. Joussen GERMANY
Future developments in retina: scientific, clinical and other challenges for the pipeline
16.15
Discussion
16.30
End of session
15.45
N. Hammel USA
ML for predicting conversion to neovascular AMD
15.50
P. Keane UK
Predicting AMD progression using AI
15.55
L. de Sisternes USA
AMD-related biomarker extraction from optical coherence tomography (OCT) and OCT angiography data
16.00
J.A. Hallak USA
AI in neovascular AMD: prediction of injection requirements
16.05
Joint Discussion – State-of-the-art AI-applications for exudative AMD
16.15
M. Pfau GERMANY
Beyond RPE-atrophy: novel biomarkers to characterize retinal atrophy progression
16.20
S. Gao USA
Prediction of disease progression in AMD to improve clinical trial design
16.25
Joint Discussion – Unmet needs and future directions in Geographic Atrophy
16.30
End of session
16.00
M. Berrocal PUERTO RICO
Rescue the View
16.01
Discussion
16.04
J. Garcia Arumi SPAIN
Lens Dislocation and Retinal Detachment in Marian Syndrome
16.05
Discussion
16.08
C. Claes BELGIUM
Oops, no way to make sclerotomies
16.09
Discussion
16.12
K. Kadonosono JAPAN
Limiting Phototoxicity During 3D Vitrectomy for Retinitis Pigmentosa
16.13
Discussion
16.16
X. Li CHINA
Air-Fluid Exchange…
16.17
Discussion
16.20
A. Maia BRAZIL
Retinal Detachment with Suprachoroidal Hemorrhage
16.21
Discussion
16.24
G. Pertile ITALY
Subretinal Injection of Membrane Blu Dual
16.25
Discussion
16.28
S. Priglinger GERMANY
Submacular Perfluoron
16.29
Discussion
16.32
S. Rizzo ITALY
Disposable Cryo
16.33
Discussion
16.36
D. Steel UK
Perfluoron Guided Subretinal TPA
16.37
Discussion
16.40
R. Tadayoni FRANCE
TBD
16.41
Discussion
16.45
End of session
08.30
C.C.W. Klaver THE NETHERLANDS
New insights from epidemiological studies
08.35
A. Tufail UK
Managing AMD patients: impact of AI-based biomarker detection in OCT scans
08.40
R. Guymer AUSTRALIA
Approaches to slow progression of intermediate AMD
08.45
Discussion
08.52
J. Mones SPAIN
Novel therapeutic approaches for neovascular AMD – better efficacy/longer duration?
08.57
C. Regillo USA
Long-acting drug delivery in nAMD: ARCHWAY phase 3 results
09.02
A. Loewenstein ISRAEL
Improving adherence and outcomes in AMD therapy: Home monitoring
09.07
Discussion
09.15
End of session
08.45
C. Creuzot-Garcher FRANCE
From Clinical trial to registry: pros and cons
08.53
M. Gillies AUSTRALIA
Long term observational study, the FRB example in AMD
09.01
D. Barthelmes SWITZERLAND
Key learnings from FRB for clinical practice
09.09
V. Daien FRANCE
From registry data to nationwide study
09.17
Discussion
09.30
End of session
Panel: Y. Le Mer FRANCE, K. Krepler AUSTRIA, I. Relimpio SPAIN, M. Romano ITALY
08.45
C. Franco Ruedas SPAIN
Presentation 1: Retinal autograph in large refractory macular hole
08.48
Discussion
08.53
C. Iovino ITALY
Presentation 2: Human amniotic membrane plug in a patient with recurrent macular hole and atrophic AMD: what’s the best surgical approach?
08.56
Discussion
09.01
J.B. Ducloyer FRANCE
Presentation 3: Gene therapy: a new complication
09.04
Discussion
09.09
M. Sommer AUSTRIA
Presentation 4: ”Fiat Lux”- A sleeve for vitrectomy light probe modification
09.12
Discussion
09.17
F. Sabatino UK
Presentation 5: ILM flap for the optic disc pit maculopathy
09.20
Discussion
09.25
Announcement of the winner
09.30
End of session
09.30
R. Schlingemann THE NETHERLANDS
New insights in the pathophysiology of diabetic macular edema in vein occlusion
09.36
P. Lanzetta ITALY
The management of macular edema in vein occlusion
09.42
J. Garcia-Arumi SPAIN
The surgical management of resistant cases of vein occlusion
09.48
F. Bandello ITALY
Is OCT-A essential in vein occlusion?
09.54
U. Schmidt-Erfurth AUSTRIA
Artificial intelligence in vascular retinal disease
10.00
Discussion
10.15
End of session
09.45
T. Williamson UK
Introduction and Natural history of RRD
09.49
J. van Meurs THE NETHERLANDS
Pre-operative assessment and management of the macula in RRD
09.53
A. Grabowska UK
Pre-operative management of the macula in PPV for RRD
09.57
D. Yorston UK
Immediate postoperative posturing
10.01
R.J. Hillier UK
Pneumatic retinopexy vs PPV
10.05
T. Williamson UK
Management of the macular displacement and macular folds
10.09
A. Grabowska UK
PVR, retinectomy and the macula
10.13
Discussion
10.30
End of course
09.45
R. Schumann GERMANY
Premacular membranes in humans: histologic evidence for different cell populations in fibrotic process
09.51
E. Pilotto ITALY
Morphofunctional evaluation in vitreomacular interface abnormalities
09.57
N. Lois UK
Vitreomacular interface abnormalities in diabetic macular oedema
10.03
R. Frisina ITALY
Surgery in idiopathic cases
10.09
M. de Smet NETHERLANDS
Can robotics contribute to the performance of vitreomacular surgery?
10.15
Discussion
10.30
End of session
10.30
B. Bodaghi FRANCE
Viral retinitis
10.36
A. Adan SPAIN
New strategies with biologics in uveitis
10.42
F. Pichi UNITED ARAB EMIRATES
OCTA in uveitis
10.48
J. van Meurs THE NETHERLANDS
Earlier antibiotic treatment is the most feasible step to improve treatment of endophthalmitis
10.54
J. Garcia-Arumi SPAIN
Surgical treatment of endophthalmitis
11.00
Discussion
11.15
End of session
10.45
G. Staurenghi ITALY
Overview on OCTA
10.51
J. Figueira PORTUGAL
OCTA in Diabetic Retinopathy
10.57
N. Eter GERMANY
OCTA in AMD
11.03
M. B. Rougier FRANCE
OCT A and optic disc
11.09
J. F. Korobelnik FRANCE
Quantification in OCT-A: what for?
11.15
Discussion
11.30
End of session
10.45
Introduction – YOURS committee
C. Dysli SWITZERLAND,
E. de Carvalho UK ,
L. Kuehlewein GERMANY,
R. Mastropasqua ITALY,
Y. Subhi DENMARK,
E. van Dijk THE NETHERLANDS
10.47
C. Iovino ITALY
Photodynamic therapy induced choroidal changes in central serous chorioretinopathy – experience from different countries
10.52
G. Ledesma Gil MEXICO/UK
Don’t throw your fluorescein angiography machine away yet
10.57
M. Bagger DENMARK
The hangman game of uveal melanoma
11.02
R. D’Aloisio ITALY
From smallfield to widefield OCTA in retinal vascular diseases
11.07
T. Nguyen THE NETHERLANDS
Two-year prospective follow-up in patients with CRB1-associated retinal dystrophies: paving the way towards gene therapy
11.12
T. Heeren UK
The end stage of Macular Telangiectasia type 2
11.17
Discussion and announcement of the winner of the Science Slam
11.28
Announcement winner Ophthalmologica lecture
11.30
End of session
12.30
R. Spaide USA
Reconsidering Pachychoroid and What it Means
13.00
M. S. Figueroa SPAIN
Plasma Rich in Growth Factors for Macular Holes in High Myopia
13.30
R. Hillier UK
Welcome (including audience poll – ‘How many audience members currently incorporate pneumatic retinopexy into their routine clinical practice?’)
13.32
P. Kertes CANADA
Review of the Pneumatic Retinopexy Trial findings
13.34
R. Hillier UK
Top line findings of the Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT) and post hoc analyses
13.36
R. Muni CANADA
Top line findings of the Retinal Displacement Detected with Fundus Autofluorescence Imaging following Pneumatic Retinopexy vs Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment Studies (INTEGRITY and ALIGN)
13.38
R. Hillier UK
The fundamentals of pneumatic retinopexy technique: Principles of intraocular gas
13.42
P. Kertes CANADA
The fundamentals of pneumatic retinopexy technique: Case selection
13.46
R. Muni CANADA, R. Hillier UK
The fundamentals of pneumatic retinopexy technique: Step-by-step surgical technique (‘the PIVOT method’)
13.54
E. Mavrikakis GREECE
The fundamentals of pneumatic retinopexy technique: Management of complications
13.58
R. Hillier UK, R. Muni CANADA, P. Kertes CANADA, E. Mavrikakis GREECE
Practical pearls and pitfalls when starting out: panel ‘round robin’ discussion
14.06
Discussion
14.15
End of session
13.30
We now know how to posture patients after detachment surgery
For: D. Yorston UK
Against: R. Hussain UK
13.45
C.C.W. Klaver THE NETHERLANDS
Myopia prevention
13.50
R. Finger GERMANY
AMD risk and progression
13.55
A. Schuster GERMANY
Glaucoma onset and progression
14.00
T. Peto UK
Diabetic eye diseases (DR & DME) onset, development of treatable stages, visual prognosis
14.05
C. Delcourt FRANCE
Diet and eye disease
14.10
Discussion
14.30
End of session
15.30
V. Sadda USA
Case 1
15.34
C. Boon THE NETHERLANDS
Case 2
15.38
R. Dolz-Marco SPAIN
Case 3
15.42
R. Gallego-Pinazo SPAIN
Case 4
15.46
S. Mrejen FRANCE
Case 5
15.50
A. Tan SINGAPORE
Case 6
15.54
S. Yzer NETHERLANDS
Case 7
15.58
Discussion
16.15
End of session
15.30
K. Rezaei USA
Zimura trial results
15.38
P. Rosenfeld USA
Apellis trial results
15.46
P. Kaiser USA
Gene therapy for neovascular AMD update
15.54
F. Bandello ITALY
Faricimab update
16.02
Discussion
16.15
End of session
15.45
Impact of COVID on Retina Care: the aftermath
Panel
A. Tufail UK
A. Lowenstein ISRAEL
F. G. Holz GERMANY
S. Wolf SWITZERLAND
J. Garcia-Arumi SPAIN
C. Mariotti ITALY
L. Kodjikian FRANCE
J. Francois Korobelnik FRANCE
15.55
How does safe spacing/PPE affect the delivery of care – can we continue to be cost-effective?
Panel
R. Hamilton UK
S. Wolf SWITZERLAND
J. Garcia-Arumi SPAIN
J. Francois Korobelnik FRANCE
16.05
Should we alter our surgical environment?
Panel
R. Tadayoni FRANCE
A. Laidlaw UK
F. G. Holz GERMANY
J. Garcia-Arumi SPAIN
C. Mariotti ITALY
16.15
Is virtual the new reality? The Good, the Bad and the Ugly – Efficiency of virtual consults, conferences, and teaching
Panel
F. G. Holz GERMANY
A. Lowenstein ISRAEL
A. Tufail UK
R. Tadayoni FRANCE
E. Midena ITALY
S. Diehl Novartis
S. Leal Bayer
16.30
End of session
16.30
A. Koh SINGAPORE
Introduction
16.31
A. Carneiro PORTUGAL
Clinical presentation: Epidemiology, differences between ethnic groups, genetic factors – CFH, HTRA1 vs others
16.36
M. Falcão PORTUGAL
Diagnosis and differentials: Current diagnostic criteria, Important differential diagnoses
16.41
G. Staurenghi ITALY
Diagnosis and differentials: Multimodal findings on OCT, ICGA, ICGA
16.46
S. Sadda USA
Treatment: PCV Anti-VEGF Monotherapy (PLANET/HAWK/HARRIER)
16.50
R. Silva PORTUGAL
Treatment: Treat and Extend for PCV (Atlantic study)
16.54
A. Koh SINGAPORE
Treatment: Combination therapy (Latest EVEREST data)
16.58
A. Koh SINGAPORE
Treatment: Current Treatment Algorithm based on Data
17.01
Discussion
17.14
R. Silva PORTUGAL
Closing points and summary
17.15
End of session
16.30
K. A. Rezaei USA
Novel Gene Therapy Approaches for Inherited Retinal Diseases
16.35
T. S. Hassan USA
MD Predictors of Endophthalmitis After Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength
16.40
A. Tufail UK
Anti-VEGF: the future is synthetic?
16.45
P. K. Kaiser USA
New anti-VEGF agents: What’s changed, What’s the same
16.50
F. Boscia ITALY
Small Gauge Surgery of Myopic Foveoschisis
16.55
S. Rizzo ITALY
Retinal Detachment: New Observations to Understand an Old Problem
17.00
Discussion
17.15
End of session
16.45
M. Michaelides UK
Phase 1/2 Clinical Trial of AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 9-month Results
16.50
F. G. Holz GERMANY
Zimura A Novel C5 Inhibitor, Significantly Reduces the Mean Rate of Geographic Atrophy Growth in the GATHER1 Clinical Trial
16.55
R. Tadayoni FRANCE
Oculis OCS-01 Phase 2 Study Results: A Topical Therapeutic for DME
17.00
R. Avery USA
RGX-314 Gene Therapy: Ongoing Phase I/IIa Interim Results
17.05
S. Sadda USA
Impact of pegcetocoplan on progression of nascent geographic atrophy in AMD
17.10
R. Tadayoni FRANCE
Investigating adverse events of intraocular inflammation with retinal vasculitis and/or retinal vascular occlusion in patients treated with brolucizumab
17.15
S. Khan UK
A Global Review of Publicly Available Datasets for Ophthalmic Imaging: Recognising Barriers to Access, Usability and Generalisability
17.20
G. Staurenghi ITALY, S. Charles USA, P. Keane UK
Innovation Discussions: 2020 News and Innovation in imaging, surgery, artificial intelligence
17.30
End of session
09.30
C. C.W. Klaver THE NETHERLANDS
Photoreceptor parameters as predictive biomarkers for geographic atrophy progression
09.37
J. Mones Spain
Lessons learned on AMD subtypes from the Eyerisk Study
09.51
C. Sanchez THE NETHERLANDS
From screen to bedside: how to implement AI in the management of retinal disease?
09.58
Discussion
10.15
End of session
09.45
W. Schrader GERMANY
Decisions in severe ocular trauma: when to reconstruct, give up reconstruction, or refer
09.50
TBC
Post-traumatic Endophthalmitis: clinical cases
09.55
TBC
Traumatic Retinal Detachment
09.59
M. Zarbin USA
Surgery for NLP eyes after open globe injury
10.05
K. Sabti KUWAIT
The Use of Endoscopy in Severe Posterior Segment Trauma
10.10
F. Fayyad JORDAN
Severe Trauma In Children
10.15
M. Mura SAUDI ARABIA
Management of post-traumatic complications
10.20
Live Discussion Q&A; Entire Group
10.30
End of session
09.45
G. Pertile ITALY
Introduction
09.47
R. Tadayoni FRANCE
My preferred peeling strategies in myopic foveoschisis and holes: how, when and why
09.54
Discussion
09.57
E. Maggio ITALY
Anatomic and functional outcomes after surgery: what should we tell the patient?
10.04
Discussion
10.07
M. Mete ITALY
What if the ILM is gone? Surgery for occuring, recurring or persisting holes after peeling
10.14
Discussion
10.17
C. Mateo SPAIN
Posterior retinal detachment in high myopia
10.24
Discussion
10.27
G. Pertile ITALY
Closing remarks and take home messages
10.30
End of session
10.30
K. Ohno-Matsui JAPAN
Ultra wide-field imaging of pathologic myopia
10.36
X. Li CHINA
Transmissions of OCT in PIC, PIC-CNV and M-CNV
10.42
L. Lu CHINA
Three years outcome of macular buckling for macularhole and foveoschisis in high myopic eyes
10.48
Y. Ikuno JAPAN
Surgical approach for myopic macular diseases
10.54
T. Ho TAIWAN
Thinking processes and practices in the management of vitreoretinal interface disorders in pathologic myopia
11.00
Discussion
11.15
End of session
10.45
D. Sarraf USA
PAMM VS AMN: Brothers in Arms or Strangers in the Night
10.51
S. Sadda USA
PEVAC
10.57
R. Schlingemann THE NETHERLANDS
Retinal vascular abnormalities associated with leakage and hard exudates, Telcaps and others
11.03
B. Leroy BELGIUM
Decision making in rare hereditary retinal disease
11.09
T. Wolfensberger SWITZERLAND
Surgical challenge-subject TBD
11.15
Discussion
11.30
End of session
10.45
E. van Dijk THE NETHERLANDS
Pathogenesis and diagnosis of CSC
10.53
Discussion
10.55
S. Yzer THE NETHERLANDS
Differential diagnosis of CSC
11.03
Discussion
11.05
C. Boon THE NETHERLANDS
Evidence-based treatment of CSC
11.13
Discussion
11.15
Questions & Answers
11.30
End of session
12.30
C. Maschi FRANCE
Diagnosis and treatment of peripheral exudative haemorrhagic chorioretinopathy
12.35
H. Annas THE NETHERLANDS
Retinal Hemeangiomas – new insights in genetics
12.39
R. Hussain UK
Photodynamic therapy for the treatment of vasoproliferativhe tumours
12.43
Discussion
12.50
E. Midena ITALY
Challenges in radiation induced macula oedema
12.54
H. Heimann UK
Photodynamic therapy of choroidal melanoma
12.58
E. Kilic THE NETHERLANDS
Molecular genetics and clinical implications in uveal melanoma
13.02
TBC
Treatment of Metastatic Uveal Melanoma
13.07
Discussion
13.15
End of session
12.45
B. Corcostegui SPAIN
Risc factors in Proliferative Vitreoretinopathy
12.51
S. Rizzo ITALY
Endotamponades in PVR
12.57
T. Wolfensberger SWITZERLAND
Retinotomy-retinectomy in PVR. When and how
13.03
J. Garcia-Arumi SPAIN
Staining and PFCL. Viscodissection in closed funnel
13.09
Discussion
13.30
End of session
12.45
R. Spaide USA
Choriocapillaris Imaging: Going Deep
12.50
S. Sadda USA
OCT Imaging: What Else for the Future?
12.55
G. Cheung SINGAPORE
Imaging in Myopia: Seeing Far into the Future
13.00
J. Kim USA
Tele-Ophthalmology: Where Are We Headed?
13.05
L. Lam USA
Augmented Reality: How will it become a reality?
13.10
D. Ting SINGAPORE
AI and Ophthalmology: Sky is the Limit
13.15
Discussion
13.30
End of session
Prof. Frank G. Holz, FEBO, FARVO
University Eye Hospital Bonn
EURETINA President
Dear Colleagues,
On behalf of myself and the board of EURETINA, I would like to extend my sincere gratitude to you for supporting EURETINA 2020 Virtual by joining us for our first online meeting on 2 – 4 October. With over 8,000 registrations to the event, we are delighted with the tremendous success of the virtual format.
We hope that you enjoyed the event from the comfort of your home and please be reminded that you can watch all your favourite and missed sessions through EURETINA playback on the virtual platform over the next three months.
I would like to take this opportunity to remind you that through the course of this year, I have initiated together with the board of EURETINA a strategic Roadmap 2025 to outline the priorities of the Society moving forward. You can find a copy of the road map in your virtual briefcase on the virtual platform and website.
The virtual Congress included a virtual Exhibition, as well as virtual Networking Lounges and the usual programme of industry sponsored Satellite Symposia. We are most grateful to our loyal sponsors for their support in this new endeavour and were glad to be able to still have the opportunity to engage directly with them during the annual meeting.
We look forward to seeing you again next year at what we hope will be a live congress. However, this year has taught us that the congress can be successful no matter what the format due to the commitment of its members and supporters.
With very best wishes,
Prof. Frank G. Holz, FEBO, FARVO
President, EURETINA
Do you have a VAT number? If so, please contact registration@euretina.org for information on how to register. Please also contact us if you are a registered business located outside of the EU.
If you are an EURETINA Member or have submitted an abstract, you may already have an account.
If you do not know the login details for this account, please click on the ‘Forgot password’ link on the registration page and they will be sent to you. Alternatively, contact the Registration Department.
Prices are in Euro & listed without VAT VAT is charged at 20% | EARLY FEE 5 Aug – 25 Sept | LATE FEE 26 Sept – 4 Oct |
EURETINA Member | 50 | 65 |
Non – Member | 95 | 110 |
Ophthalmic Nurse / Technician* | 50 | 65 |
*Documentation such as a work ID or verification letter from your hospital is required and must be uploaded during the registration process for approval.Registration Information
CME credits will only be awarded to those who attended the live meeting from 2-4 October 2020